

1 **Running Title:** Genome recombination of SARS-CoV-2 variants

2 **Keywords:** SARS-CoV-2, Genome recombination, Alpha variant, Delta variant

3

4 **Title: Genome Recombination between Delta and Alpha Variants of Severe Acute**

5 **Respiratory Syndrome Coronavirus 2 (SARS-CoV-2)**

6

7 **Authors:** Tsuyoshi Sekizuka^a, Ph.D., Kentaro Itokawa^a, Ph.D., Masumichi Saito, Ph.D.,

8 Michitsugu Shimatani, M.D., Shutoku Matsuyama, Ph.D., Hideki Hasegawa, M.D., Ph.D.,

9 Tomoya Saito, M.D., Ph.D., and Makoto Kuroda[#] Ph.D. and COVID-19 Genomic Surveillance

10 Network in Japan (COG-JP).

11 **Author Affiliations:**

12 National Institute of Infectious Diseases, Tokyo, Japan (T. Sekizuka, K. Itokawa, M. Saito, M.

13 Shimatani, S. Matsuyama, H. Hasegawa, T. Saito, M. Kuroda)

14 ^aThese authors contributed equally to this article.

15

16 **#Corresponding Author:**

17 Makoto Kuroda, Ph.D.

18 Address for correspondence: Pathogen Genomics Center, National Institute of Infectious

19 Diseases, 1-23-1 Toyama, Shinjuku-ku, Tokyo 162-8640, Japan

20 Tel: +81-3-5285-1111

21 Fax: +81-3-5285-1166

22 E-mail: makokuro@niid.go.jp

23

24 **Abstract**

25 Prominent genomic recombination has been observed between the Delta and Alpha variants of
26 severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) isolated from clinical
27 specimens in Japan. It is necessary to intensively study such marked genetic variations and
28 characterize the emerging variants after careful verification of their lineage and clade
29 assignment.

30

31 **Text**

32 **Ethics Statement**

33 The study protocol was approved by the National Institute of Infectious Diseases, Japan
34 (Approval no. 1091). The ethics committee waived the requirement for written consent with
35 respect to research on viral genome sequences.

36 **Course of the Study**

37 We conducted a genome surveillance of the severe acute respiratory syndrome coronavirus 2
38 (SARS-CoV-2) with help from the local public health centers, laboratories in research institutes,
39 commercial laboratories (1, 2), and airport quarantine stations (3). The coronavirus disease-19
40 (COVID-19) Genomic Surveillance Network in Japan (COG-JP) has consistently monitored the
41 prevalence of the Phylogenetic Assignment of Named Global Outbreak (PANGO) lineages of
42 SARS-CoV-2 from the first COVID-19 case (January 15, 2020) to recent cases (September 30,
43 2021). Until now, 120,476 domestic and 2,018 quarantine isolates have been deposited in the
44 Global Initiative on Sharing All Influenza Data (GISAID) EpiCoV database (1, 2). Whole-
45 genome sequences were assigned to the SARS-CoV-2 isolates (≥ 29 kb genome size) obtained

46 from domestic COVID-19-positive patients in Japan (n = 120,476), according to the PANGO
47 lineage definition (v3.1.14, 2021-09-28) (4).

48 **Observations and Discussions**

49 During the surveillance, we monitored several variants of concern (VOCs) of the PANGO
50 lineage. We found six unique specimens (Fig. 1) among the 21A (Delta) clade isolates that
51 exhibited a low quality assignment (“not determined” or “none”) in the PANGO lineage, even
52 though their genome sequences had been completely determined with high read coverage
53 throughout the whole genome region. A detailed genome alignment by Nextclade (5) suggested
54 that despite being clonal isolates of the 21A (Delta) clade, these six isolates show identical
55 mutation profiles with 20I (Alpha, V1), particularly between the *ORF6* and *N* genes, located
56 towards the latter part of the SARS-CoV-2 genome (Fig. 1). Additionally, the alignment clearly
57 revealed a possible recombination spot between the *ORF6* and *ORF7a* genes (Fig. 1). However,
58 the next generation sequencing (NGS)-based read mapping analysis did not indicate the presence
59 of any heterogeneous mix of alleles in the clinical specimens, suggesting that these patients had
60 not acquired multiple variant infections with 21A (Delta) and 20I (Alpha, V1) clades at the acute
61 stage of the infection (Fig. 2).

62 Interestingly, all six clinical isolates that exhibit the abovementioned recombination were
63 detected around mid-August 2021. Even though the mutation profiles point towards the clonal
64 nature of these six isolates (Fig. 1), there is no epidemiological link among the patients.
65 Incidentally, the two variants, namely 21A (Delta) and 20I (Alpha), were detected in 93% and
66 5% of the total specimens, respectively, in mid-August 2021 in Japan (6), suggesting the
67 possibility of multi-variant infection in a single patient leading to such a recombination event.
68 However, we have not yet identified a potential patient with mixed infection, i.e., one who has

69 tested double positive in the variant polymerase chain reaction (PCR) test. Furthermore, the
70 number of COVID-19-positive patients has been significantly decreasing in Japan since early
71 October 2021. In parallel, such a recombinant isolate has not been detected thus far, indicating
72 that it might be contained compared with other domestic Delta variants.

73 A recent report by Gribble et al. demonstrated that recombination is a critical event for
74 creating the coronavirus diversity, and RNA proofreading exoribonuclease (nsp14-ExoN) is
75 responsible for generating the recombination frequency as well as the altered recombination
76 products in the in vitro culture experiments (7). The report has also described eight potential
77 recombination hotspots at the microhomologous sequence of the SARS-CoV-2 genome. In fact,
78 one of the hotspots, which lies between *ORF6* and *ORF7a*, could be the target site responsible
79 for the recombination event observed in the current study. Interestingly, the recombination
80 variant detected in this study carries a spike protein identical to the one in the domestic Delta
81 variant, thereby suggesting that further risks would not be concerned with infectivity and
82 immune escape.

83 The detection of SARS-CoV-2 variants with *ORF7a*, *ORF7b*, and *ORF8* deletions (8-11) can
84 explain the occurrence of the abovementioned recombination event. In fact, the hotspots around
85 *ORF7a* can facilitate the generation of a novel isolate that exhibits different genetic profiles
86 owing to co-infection by distinct variants in the COVID-19 patient. In addition to the six isolates
87 mentioned in this study, we also investigated the total deposits in GISAID (by 2021-09-30) for
88 other possible genomic recombinations. We found a USA isolate [hCoV-19/USA/MO-CDC-
89 LC0213262/2021 (EPI_ISL_4164992|2021-08-07)] portraying a recombination between the
90 Delta and Alpha variants in *ORF7a*, but we could not reconfirm the validity of the event because
91 we were unable to obtain the raw NGS sequencing reads for analysis.

92 **Conclusions**

93 In conclusion, this is the first identification of a novel recombination SARS-CoV-2 variant
94 between the 21A (Delta) and 20I (Alpha, V1) clades in domestic clinical specimens. As
95 suggested by previous in vitro culture experiments (7), such a recombination can possibly be
96 generated in the real world. Therefore, the simple PANGO and clade assignment might mis-
97 identify notable variants based upon ordinary genome surveillance, and we must intensively
98 monitor and carefully inspect such marked genetic variations to ensure their proper
99 characterization.

100

101 **Acknowledgments**

102 We would like to thank Rina Tanaka, Satsuki Eto, Risa Someno, Akina Ogamino, Naomi
103 Nojiri, Hazuka Yoshida, Tomoko Ishihara, Tadaki Suzuki and Nozomi Takeshita for the whole-
104 genome sequencing and data curation of the SARS-CoV-2 specimens. This work was supported
105 by a Grant-in-Aid from the Japan Agency for Medical Research and the Development Research
106 Program on Emerging and Re-emerging Infectious Diseases (JP21fk0108103) and a grant from
107 the Ministry of Health, Labor, and Welfare, Japan (19HA1001 and 20HA2007). Finally, we
108 would like to thank all the researchers who have deposited and shared genomic data of SARS-
109 CoV-2 on GISAID.

110

111 **Disclaimers:** The opinions expressed by the authors contributing to this article do not
112 necessarily reflect the opinions of the Centers for Disease Control and Prevention or the
113 institutions with which the authors are affiliated.

114

115 **Data availability**

116 Raw NGS sequencing reads have been deposited in the DNA Data Bank of Japan (DDBJ;
117 accession number: DRA012825), as shown in the Table.

118

119 **Author Bio**

120 Dr. Tsuyoshi Sekizuka is a chief at the National Institute of Infectious Diseases in
121 Shinjuku-ku, Tokyo, Japan. His main research interest is pathogen genomics.

122

123 **References**

- 124 1. Itokawa K, Sekizuka T, Hashino M, Tanaka R, Kuroda M. Disentangling primer
125 interactions improves SARS-CoV-2 genome sequencing by multiplex tiling PCR. *PLoS One*.
126 2020;15(9):e0239403.
- 127 2. Sekizuka T, Itokawa K, Hashino M, Kawano-Sugaya T, Tanaka R, Yatsu K, et al. A
128 Genome Epidemiological Study of SARS-CoV-2 Introduction into Japan. *mSphere*. 2020
129 November 11;5(6):e00786-20.
- 130 3. Sekizuka T, Itokawa K, Yatsu K, Tanaka R, Hashino M, Kawano-Sugaya T, et al.
131 COVID-19 genome surveillance at international airport quarantine stations in Japan. *J Travel*
132 *Med*. 2021 Feb 23;28(2):taaa217.
- 133 4. Rambaut A, Holmes EC, O'Toole A, Hill V, McCrone JT, Ruis C, et al. A dynamic
134 nomenclature proposal for SARS-CoV-2 lineages to assist genomic epidemiology. *Nat*
135 *Microbiol*. 2020 Nov;5(11):1403-7.
- 136 5. Hadfield J, Megill C, Bell SM, Huddleston J, Potter B, Callender C, et al. Nextstrain:
137 real-time tracking of pathogen evolution. *Bioinformatics*. 2018 Dec 1;34(23):4121-3.

- 138 6. outbreak.info. <https://outbreakinfo/location-reports?loc=JPN>. 2021.
- 139 7. Gribble J, Stevens LJ, Agostini ML, Anderson-Daniels J, Chappell JD, Lu X, et al. The
140 coronavirus proofreading exoribonuclease mediates extensive viral recombination. *PLoS Pathog.*
141 2021 Jan;17(1):e1009226.
- 142 8. Addetia A, Xie H, Roychoudhury P, Shrestha L, Loprieno M, Huang ML, et al.
143 Identification of multiple large deletions in ORF7a resulting in in-frame gene fusions in clinical
144 SARS-CoV-2 isolates. *J Clin Virol.* 2020 Aug;129:104523.
- 145 9. Tse H, Wong SC, Ip KF, Cheng VC, To KK, Lung DC, et al. Genome Sequences of
146 Three SARS-CoV-2 ORF7a Deletion Variants Obtained from Patients in Hong Kong. *Microbiol*
147 *Resour Announc.* 2021 Apr 15;10(15).
- 148 10. Mazur-Panasiuk N, Rabalski L, Gromowski T, Nowicki G, Kowalski M, Wydmanski W,
149 et al. Expansion of a SARS-CoV-2 Delta variant with an 872 nt deletion encompassing ORF7a,
150 ORF7b and ORF8, Poland, July to August 2021. *Euro Surveill.* 2021 Sep;26(39).
- 151 11. Neches RY, Kyrpides NC, Ouzounis CA. Atypical Divergence of SARS-CoV-2 Orf8
152 from Orf7a within the Coronavirus Lineage Suggests Potential Stealthy Viral Strategies in
153 Immune Evasion. *mBio.* 2021 Jan 19;12(1).

154

155

156

Table: Summary information of the recombination variant isolates of SARS-CoV-2 ¹

Isolate	Sampling date (yyyy-mm)	Clade	Lineage (PANGOLIN ² , 2021-09-28)	GISAID ³ ID	NGS ⁴ raw reads (fastq)
PG-107020	2021-08	21A (Delta)	None	EPI_ISL_4882472	DRR321268
PG-113440	2021-09	21A (Delta)	None	EPI_ISL_4882473	DRR321269
PG-133737	2021-08	21A (Delta)	None	EPI_ISL_4882477	DRR321273
PG-122116	2021-08	21A (Delta)	None	EPI_ISL_4882474	DRR321270
PG-128229	2021-08	21A (Delta)	None	EPI_ISL_4882476	DRR321272
PG-126853	2021-08	21A (Delta)	None	EPI_ISL_4882475	DRR321271

^[1] SARS-CoV-2: Severe acute respiratory syndrome coronavirus 2

^[2] PANGOLIN: Phylogenetic Assignment of Named Global Outbreak Lineages

^[3] GISAID: Global Initiative on Sharing All Influenza Data

^[4] NGS: Next generation sequencing


157

158

159

160


161



162

163 **Figure 1.** Clade assignment and pair-wise genome alignment of severe acute respiratory
 164 syndrome coronavirus 2 (SARS-CoV-2) samples were performed using Nextclade analysis (5).
 165 In a comparison with the control for B.1.1.7 Alpha variant (PG-58832) and B.1.617.2 Delta
 166 variant (PG-48062), Nextclade alignment showed that six isolates (highlighted in red) have been
 167 assigned in the 21A (Delta) clade, but their mutation profiles after the *ORF7a* gene suggest
 168 identical profiling with the B.1.1.7 Alpha variant (PG-58832). The possible recombination point
 169 is shown as red broken line.

170



179 (A: red, G: yellow, C: blue, and T: green) on the read mapping area in dark gray. Co-infection
180 samples with Alpha and Delta variants were prepared virtually for comparison.